Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.68 |
| ▸ | NAALAD2 | Q9Y3Q0 | 7/20 | 0.68 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22037239 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19209760 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14550469 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12654762 | 0.89 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14115633 | 0.89 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12291706 | 0.88 | FOLH1 (0.50) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936652 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22636039 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14331633 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936625 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-11-04 | — | — | US | disclosed |
| US-20210322388-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| US-11083710-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20140154702-A1 | Methods For Treating Cancer Using Combination Therapies | ENDOCYTE INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140073763-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010045598-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100055735-A1 | EX VIVO FLOW CYTOMETRY METHOD AND DEVICE | LOW PHILIP STEWART | 2010-03-04 | — | — | US | disclosed |
| US-20100055735-A1 | EX VIVO FLOW CYTOMETRY METHOD AND DEVICE | LOW PHILIP STEWART | 2010-03-04 | — | — | US | disclosed |
| WO-2009026177-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| US-7381745-B2 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY (US) | 2008-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083710-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 32/4885RIMKLA 801/4885 |
| US-20210322388-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20140073763-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | FOLH1 1/4885NAALAD2 67/4885RIMKLA 110/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.